STRYKER CORP 8-K

What Happened
Stryker Corporation filed a Form 8‑K on June 26, 2026 announcing a reorganization that creates a new Ortho Tech business by combining the orthopaedic instruments portfolio from its Instruments business with Mako and enabling technologies from Other Orthopaedics. The company will continue to report two reportable segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics. To reflect this change in segment reporting, Stryker is recasting its consolidated financial statements for each of the three years in the period ended December 31, 2025; the recast is included as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: June 26, 2026; recast covers the three years ended Dec. 31, 2025.
• New business: “Ortho Tech” combines orthopaedic instruments + Mako and enabling technologies (power tools, cutting accessories, etc.).
• Reportable segments remain two: MedSurg & Neurotechnology; Orthopaedics.
• The recast is for informational purposes only and is not a restatement of previously issued audited consolidated financial statements; Exhibit 99.1 contains the recast items and the auditor’s consent is included.

Why It Matters
For investors, the reorganization changes how Stryker presents revenue and results by segment, so historical segment comparability will be updated through the recast. The filing does not change audited totals in the 2025 Annual Report, but analysts and investors should review the recast (Exhibit 99.1) and Stryker’s subsequent filings (notably the Q1 2026 Form 10‑Q) to understand the new segment presentation and any impacts on segment-level trends and metrics.